Results 131 to 140 of about 14,308 (181)

Scleromyxedema: Treatment with interferon alfa

Journal of the American Academy of Dermatology, 1999
Scleromyxedema is a variant of papular mucinosis characterized by fibroblast proliferation and mucin deposition in the dermis. Historically, it has been very difficult to treat and can cause significant morbidity and mortality with systemic involvement.
J A, Tschen, J R, Chang
openaire   +2 more sources

Combination therapy with interferon alfa and ribavirin in interferon alfa relapsers

1996
Not ...
Ricchiuti A, Ciccorossi P, Costa F, Bellini M, Tumino E, Petruccelli S, Maggi F, Vatteroni L, PISTELLO, MAURO, Bendinelli M, Maltinti G, Marchi S.   +11 more
openaire   +2 more sources

Interferon-alfa for chronic myeloid leukemia

Seminars in Hematology, 2003
Interferon-alfa (IFNalpha) became the first-line agent for the treatment of chronic myeloid leukemia (CML) because it prolongs survival significantly compared to conventional chemotherapy (CHT). Responses to IFNalpha and the benefits from achieving a response are greater in low-risk than in high-risk patients.
Baccarani, Michele, Russo, Domenico, Rosti, Gianantonio, Martinelli, Giovanni   +3 more
openaire   +3 more sources

Interferon alfa-2a.

British journal of hospital medicine, 1997
Interferon alfa-2a shows both antiviral and antitumoral activity, but its role in the treatment of many conditions remains controversial. It is, however, the treatment of choice for chronic, active hepatitis B, chronic hepatitis C and AIDS-related Kaposi's sarcoma, and is also effective in metastatic renal carcinoma and chronic myelogenous leukaemia ...
C D, Williams, D C, Linch
openaire   +1 more source

Interferon alfa, peginterferon alfa and retinopathy.

Prescrire international, 2006
(1) Retinal damage is a known adverse effect of interferon alfa. (2) Similar adverse effects have been reported with pegylated interferon alfa. The disorders generally regress within a few months, despite continued treatment.
openaire   +1 more source

Interferon ALFA

Neurology, 1996
Ken Ikeda, Masao Kinoshitz
openaire   +1 more source

INTERFERON ALFA

Reactions Weekly, 2015
openaire   +2 more sources

Interferon Alfa-2b

2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +1 more source

THE TREATMENT OF MYELOFIBROSIS WITH ALFA‐INTERFERON

British Journal of Haematology, 1991
D, McCarthy, J, Clark, F, Giles
openaire   +2 more sources

Interferon Alfa

2010
Jason Grebely, Greg Dore
openaire   +1 more source